Evidence map›Paper›PMID 35656776›Full record

ArticleBrain : a journal of neurology2022

A Mendelian randomization study investigating the causal role of inflammation on Parkinson's disease.

Daniele Bottigliengo, Luisa Foco, Philip Seibler, Christine Klein, Inke R König, Fabiola Del Greco M

Open access · hybridAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 3 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Observational
  5. Sex-dependent impact ofGenes & diseases · 2026
    Article
  6. Review
  7. Article
  8. Genetic analysis of neurodegenerative diseases.The Journal of clinical investigation · 2026
    Review
  9. Peripheral inflammation predicts motor, cognitive, and disease progression in Parkinson's disease: A 4-year longitudinal study from the PPMI cohorts.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Daniele BottigliengoInstitute for Biomedicine, Eurac Research, Bolzano/Bozen, Italy.ORCID 0000-0002-8802-3834
Luisa FocoInstitute for Biomedicine, Eurac Research, Bolzano/Bozen, Italy.
Philip SeiblerInstitute of Neurogenetics, University of Lübeck and University Hospital of Schleswig-Holstein, Lübeck, Germany.
Christine KleinInstitute of Neurogenetics, University of Lübeck and University Hospital of Schleswig-Holstein, Lübeck, Germany.
Inke R KönigInstitute of Medical Biometry and Statistics, University of Lübeck and University Hospital of Schleswig-Holstein, Lübeck, Germany.
Fabiola Del Greco MInstitute for Biomedicine, Eurac Research, Bolzano/Bozen, Italy.
Eurac Research · ITUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is increasing evidence for inflammation as a determinant in the pathogenesis of Parkinson's disease, but its role in parkinsonian neurodegeneration remains elusive. It is not clear whether inflammatory cascades are causes or consequences of dopamine neuron death. In the present study, we aim to perform an in-depth statistical investigation of the causal relationship between inflammation and Parkinson's disease using a two-sample Mendelian randomization design. Genetic instruments were selected using summary-level data from the largest genome-wide association studies to date (sample size ranging from 13 955 to 204 402 individuals) conducted on a European population for the following inflammation biomarkers: C-reactive protein, interleukin-6, interleukin 1 receptor antagonist and tumour necrosis factor α. Genetic association data on Parkinson's disease (56 306 cases and 1 417 791 controls) and age at onset of Parkinson's disease (28 568 cases) were obtained from the International Parkinson's Disease Genomics Consortium. On primary analysis, causal associations were estimated on sets of strong (P-value < 5 × 10-8; F-statistic > 10) and independent (linkage disequilibrium r2 < 0.001) genetic instruments using the inverse-variance weighted method. In sensitivity analysis, we estimated causal effects using robust Mendelian randomization methods and after removing pleiotropic genetic variants. Reverse causation was also explored. We repeated the analysis on different data sources for inflammatory biomarkers to check the consistency of the findings. In all the three data sources selected for interleukin-6, we found statistical evidence for an earlier age at onset of Parkinson's disease associated with increased interleukin-6 concentration [years difference per 1 log-unit increase = -2.364, 95% confidence interval (CI) = -4.789-0.060; years difference per 1 log-unit increase = -2.011, 95% CI = -3.706 to -0.317; years difference per 1 log-unit increase = -1.569, 95% CI = -2.891 to -0.247]. We did not observe any statistical evidence for causal effects of C-reactive protein, interleukin 1 receptor antagonist and tumour necrosis factor α on both Parkinson's disease and its age at onset. Results after excluding possible pleiotropic genetic variants were consistent with findings from primary analyses. When investigating reverse causation, we did not find evidence for a causal effect of Parkinson's disease or age at onset on any biomarkers of inflammation. We found evidence for a causal association between the onset of Parkinson's disease and interleukin-6. The findings of this study suggest that the pro-inflammatory activity of the interleukin-6 cytokine could be a determinant of prodromal Parkinson's disease.

Indexed as

Mendelian Randomization AnalysisParkinson DiseaseBiomarkersC-Reactive ProteinGenome-Wide Association StudyHumansInflammationInterleukin-6Polymorphism, Single NucleotideReceptors, Interleukin-1Tumor Necrosis Factor-alphaBiomarkersC-Reactive ProteinInterleukin-6Receptors, Interleukin-1Tumor Necrosis Factor-alphaage at onset of Parkinson’s diseasecausal inferenceinflammationMendelian randomizationParkinson’s disease

Identifiers

PMID35656776
PMCPMC9586538
OpenAlexW4281801257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.